{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:06:18Z","timestamp":1779883578663,"version":"3.53.1"},"reference-count":66,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>The neurotoxin botulinum toxin type A (BoNT\/A), produced by the bacteria Clostridium botulinum, is commonly injected intramuscularly (IM) for the management of chronic muscle hyperactivity, such as post-stroke spasticity. New indications such as peripheral neuropathic pain require alternative routes of BoNT\/A administration, such as subcutaneous (SC) or intradermal (ID). While IM BoNT\/A injections may elicit anti-drug-antibodies (ADAs), their occurrence following SC or ID administration is unknown. Therefore, we investigated whether repeated SC or ID injections of 150 kDa BoNT\/A can elicit ADAs in a dose-dependent manner, and whether these differ depending upon the route of administration. Mice were injected 5 times ID or SC with 150 kDa BoNT\/A or, for higher doses, inactive mutant BoNT\/A (DRBoNT\/A) or inactivated toxoid (IA-BoNT\/A). Total ADAs were analyzed by an immunoassay and the subgroup of neutralizing ADAs by an in vivo digit abduction score (DAS) assay following a challenge of 0.6 U BoNT\/A IM. DRBoNT\/A and IA-BoNT\/A injections elicit ADAs (22.7 U\/mL vs. 460.5 U\/mL for ID; 4.7 U\/mL vs. 339.4 U\/mL for SC), while therapeutic doses of 150 kDa BoNT\/A do not. Whereas mice with repeated 150 kDa BoNT\/A injections at therapeutic dose show an unrestricted DAS of 3.7 (ID) or 3.4 (SC), mice injected repeatedly with 1.8 \u00b5g\/kg DRBoNT\/A or 500 \u00b5g\/kg IA-BoNT\/A show only a minimal DAS of \u22640.7, indicating a high titer of neutralizing ADAs. No differences were observed between administration routes. Accordingly, repeated ID or SC injections of pure 150 kDa BoNT\/A at therapeutic doses fail to induce ADA formation in mice. On the other hand, DRBoNT\/A ID injections induce higher ADA concentrations than SC, but generate similar amounts of neutralizing ADAs. IA-BoNT\/A injections induce ADAs and neutralizing ADAs similarly after ID and SC injections. ADA development at intermediate BoNT\/A doses can be higher after ID injection, but does not lead to differences in neutralizing ADAs. Our data demonstrate that the antibody response to botulinum toxin depends predominantly on the protein load, and less on the administration route.<\/jats:p>","DOI":"10.3390\/toxins18060245","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:03:27Z","timestamp":1779879807000},"page":"245","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intradermal and Subcutaneous Botulinum Toxin Type A Injections Do Not Differ in the Induction of Neutralizing Antibody Formation"],"prefix":"10.3390","volume":"18","author":[{"given":"Stefanie","family":"Honndorf","sequence":"first","affiliation":[{"name":"Neurotoxin & Biotechnology Development, Merz Therapeutics GmbH, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Moser","sequence":"additional","affiliation":[{"name":"Neurotoxin & Biotechnology Development, Merz Therapeutics GmbH, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fink","sequence":"additional","affiliation":[{"name":"Neurotoxin & Biotechnology Development, Merz Therapeutics GmbH, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","first-page":"219","article-title":"Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins","volume":"19","author":"Atassi","year":"1999","journal-title":"Crit. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/mda.2002.24423","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine","volume":"48","author":"Binder","year":"2002","journal-title":"Disease-a-Month"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison with OnabotulinumtoxinA and Placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","article-title":"Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia","volume":"67","author":"Jost","year":"2007","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/14656566.2.10.1649","article-title":"Review of botulinum toxin type A and its clinical applications in migraine headache","volume":"2","author":"Silberstein","year":"2001","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"jrm00138","DOI":"10.2340\/16501977-2760","article-title":"Sustained efficacy of incobotulinumtoxina repeated injections for upper-limb post-stroke spasticity: A post hoc analysis","volume":"53","author":"Kanovsky","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: Mechanisms, prediction and reduction","volume":"60","author":"Sethu","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2000-12955","article-title":"Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy","volume":"31","author":"Herrmann","year":"2000","journal-title":"Neuropediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.17219\/acem\/90764","article-title":"How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA","volume":"28","author":"Przydacz","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R&D"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14316","DOI":"10.1021\/bi701564f","article-title":"Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E","volume":"46","author":"Kukreja","year":"2007","journal-title":"Biochemistry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/iai.64.5.1589-1594.1996","article-title":"Molecular composition of Clostridium botulinum type A progenitor toxins","volume":"64","author":"Inoue","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1504\/TBJ.2008.018951","article-title":"How do the Botulinum Neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action","volume":"1","author":"Poulain","year":"2008","journal-title":"Botulinum J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/mp0601244","article-title":"Stability of the Clostridium botulinum type A neurotoxin complex: An empirical phase diagram based approach","volume":"4","author":"Brandau","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum neurotoxin is shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"ref_19","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: A help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.toxicon.2009.01.017","article-title":"Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins","volume":"53","author":"Kukreja","year":"2009","journal-title":"Toxicon"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Davies, J.R., Liu, S.M., and Acharya, K.R. (2018). Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics. Toxins, 10.","DOI":"10.3390\/toxins10100421"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20806","DOI":"10.1038\/s41598-023-48008-5","article-title":"A human bispecific antibody neutralizes botulinum neurotoxin serotype A","volume":"13","author":"Lu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","article-title":"Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies","volume":"216","author":"Atassi","year":"2011","journal-title":"Immunobiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","article-title":"Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A","volume":"44","author":"Dolimbek","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","article-title":"Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment","volume":"45","author":"Atassi","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00415-022-11395-2","article-title":"Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin","volume":"270","author":"Hefter","year":"2023","journal-title":"J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","article-title":"Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions","volume":"8","author":"Aoki","year":"2001","journal-title":"Eur. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_31","unstructured":"Fink, K., Eisele, K.H., Mander, G.J., and Taylor, H.V. (2009). The mouse hemidiaphragm assay detects neutralizing anti-botulinum neurotoxin type A antibodies with higher sensitivity than the mouse protection assay. Proceedings of the World Congress of the International Society of Physical and Rehabilitation Medicine, Istanbul, Turkey, 13\u201317 June 2009, International Society of Physical and Rehabilitation Medicine location."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R&D"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to Botulinum Toxin Type A: A Systematic Review with Meta-Analysis Across Therapeutic Indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Berweck, S., Banach, M., Gaebler-Spira, D., Chambers, H.G., Schroeder, A.S., Geister, T.L., Althaus, M., Hanschmann, A., Vacchelli, M., and Bonfert, M.V. (2022). Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis. Toxins, 14.","DOI":"10.3390\/toxins14090585"},{"key":"ref_36","unstructured":"(2026, May 13). A Parallel-Group Treatment, Proof-of-Concept Phase 2, Multicenter, Double-Blind, Randomized Two-Arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared with Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older with Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06091020."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13944","DOI":"10.1111\/dth.13944","article-title":"Intradermal injection of incobotulinumtoxinA for face lifting","volume":"33","author":"Wanitphakdeedecha","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0041-0101(01)00101-5","article-title":"A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice","volume":"39","author":"Aoki","year":"2001","journal-title":"Toxicon"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.toxicon.2013.05.004","article-title":"The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis","volume":"71","author":"Broide","year":"2013","journal-title":"Toxicon"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1615\/CritRevImmunol.v27.i4.30","article-title":"Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action","volume":"27","author":"Atassi","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1097\/00002508-200211001-00004","article-title":"Considering the immune response to botulinum toxin","volume":"18","author":"Critchfield","year":"2002","journal-title":"Clin. J. Pain."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","article-title":"Immunological aspects of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s13555-025-01530-y","article-title":"A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A","volume":"15","author":"Srinoulprasert","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_44","unstructured":"(2026, March 17). FDA Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125360s110lbl.pdf."},{"key":"ref_45","unstructured":"(2026, May 13). Subcutaneous Botulinum Toxin for Cutaneous Allodynia, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00822926."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-immunol-051116-052215","article-title":"Antigen-Presenting Cells in the Skin","volume":"35","author":"Kashem","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bono, F., Mazza, M.R., Magro, G., Spano, G., Idone, G., Laterza, V., Tedeschi, D., Pucci, F., Gambardella, A., and Sarica, A. (2023). Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Toxins, 15.","DOI":"10.3390\/toxins15050324"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1504\/TBJ.2008.026477","article-title":"Expression, purification and comparative characterisation of enzymatically deactivated recombinant botulinum neurotoxin type A","volume":"1","author":"Yang","year":"2008","journal-title":"Botulinum J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.toxicon.2013.06.014","article-title":"Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions","volume":"72","author":"Baskaran","year":"2013","journal-title":"Toxicon"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12984-026-01895-x","article-title":"Electrical or magnetic nerve stimulation enhance the BoNT\/A-mediated muscle paralysis","volume":"23","author":"Honndorf","year":"2026","journal-title":"J. Neuroeng. Rehabil."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14746","DOI":"10.1038\/s41598-017-14997-3","article-title":"Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures","volume":"7","author":"Pingel","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcpt.12351","article-title":"Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats","volume":"116","author":"Torii","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.toxcx.2020.100029","article-title":"Optimization of the rat digit abduction score (DAS) assay: Evaluation of botulinum neurotoxin activity in the gastrocnemius lateralis, peronei, and extensor digitorum longus","volume":"6","author":"Cornet","year":"2020","journal-title":"Toxicon X"},{"key":"ref_54","unstructured":"Taconic Biosciences, I. (2026, February 17). BALB\/c Growth Chart. Available online: https:\/\/www.taconic.com\/products\/mouse-rat\/standard-strains-and-stocks\/balbc#tabsmobiledropdown-a6cb9ba47d-item-b96b1003ea-tab."},{"key":"ref_55","unstructured":"Doyle, G.R., and McCutcheon, J.A. (2025, November 18). 7.2 Parenteral Medications and Preparing Medications from Ampules and Vials. Available online: https:\/\/opentextbc.ca\/clinicalskills\/chapter\/safe-injection-administration-and-preparing-medication-from-ampules-and-vials\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/infdis\/jiu841","article-title":"Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults","volume":"211","author":"Troy","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_58","first-page":"238","article-title":"Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit","volume":"9","author":"Frevert","year":"2006","journal-title":"Neurotox. Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kanovsky, P., Elovic, E.P., Hanschmann, A., Pulte, I., Althaus, M., Hiersemenzel, R., and Marciniak, C. (2020). Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.615706"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity Associated with Botulinum Toxin Treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies\u2014Therapeutic consequences","volume":"147","author":"Goschel","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/mds.20021","article-title":"Detection of antibodies against botulinum toxins","volume":"19","author":"Sesardic","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/DSS.0000000000004293","article-title":"Immunogenicity of Botulinum Toxin A: Insights","volume":"50","author":"Rahman","year":"2024","journal-title":"Dermatol. Surg."},{"key":"ref_64","unstructured":"(2026, May 13). Safety and Efficacy Study of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01157377."},{"key":"ref_65","unstructured":"(2026, May 13). A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06625060."},{"key":"ref_66","unstructured":"(2026, May 13). A Phase II, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06937931."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/6\/245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:15:35Z","timestamp":1779880535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/6\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["toxins18060245"],"URL":"https:\/\/doi.org\/10.3390\/toxins18060245","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}